Notoginsenoside Ft1 acts as a TGR5 agonist but FXR antagonist to alleviate high fat diet-induced obesity and insulin resistance in mice

• 作者: Lili Ding Qiaoling Yang Eryun Zhang Yangmeng Wang Siming Sun Yingbo Yang Tong Tian Zhengcai Ju Linshan Jiang Xunjiang Wang Zhengtao Wang Wendong Huang Li Yang
• 来源期刊: 药学学报（英文版）
• 年，卷（期）: 2021,（6）
• 所属期刊栏目: Original articles
• 页码范围: 1541-1554
• 页数: 14页
• 语种: 英文

摘要

Obesity and its associated complications are highly related to a current public health crisis around the world.A growing body of evidence has indicated that G-protein coupled bile acid (BA) re-ceptor TGR5 (also known as Gpbar-1) is a potential drug target to treat obesity and associated metabolic disorders.We have identified notoginsenoside Ft1 (Ft1) from Panax notoginseng as an agonist of TGR5 in vitro.However,the pharmacological effects of Ft1 on diet-induced obese (DIO) mice and the under-lying mechanisms are still elusive.Here we show that Ftl (100 mg/100 diet) increased adipose lipolysis,promoted fat browning in inguinal adipose tissue and induced glucagon-like peptide-1 (GLP-1) secretion in the ileum of wild type but not Tgr5-/-obese mice.In addition,Ftl elevated serum free and taurine-conjugated bile acids (BAs) by antagonizing Fxr transcriptional activities in the ileum to activate Tgr5 in the adipose tissues.The metabolic benefits of Ftl were abolished in Cyp27a1-/-mice which have much lower BA levels.These results identify Ftl as a single compound with opposite activities on two key BA receptors to alleviate high fat diet-induced obesity and insulin resistance in mice.